Company description

ALPN, or Alpine Immune Sciences, Inc., is a biotechnology company that focuses on the discovery and development of therapies for patients suffering from serious and life-threatening diseases. The company's proprietary technology, called Variant Immunoglobulin Domain (vIgD), allows it to design and engineer a diverse array of therapeutic candidates. ALPN's pipeline consists of novel immune modulatory proteins that have the potential to treat a wide range of diseases, including autoimmune disorders, oncology, and inflammatory diseases. With a strong team of experienced leaders and scientists, ALPN is committed to advancing its innovative approach to drug development and bringing much-needed treatments to patients in need. Their dedication to improving patient outcomes and addressing unmet medical needs has positioned ALPN as a leading player in the biotechnology industry. As the company continues to progress in its research and development efforts, investors can look forward to potential breakthroughs and significant growth opportunities in the future.